Blog

Search results for 'Nicholi': Page 36

Apr 9, 2020

Whistleblower doctors say coronavirus reinfection even deadlier

Posted by in category: biotech/medical

The doctor added that the virus has “outsmarted all of us,” since he says it’s able to hide symptoms for up to 24 days — which contradicts current guidance that the incubation period is two weeks.


Chinese doctors sounding the alarm on the coronavirus say the illness could be even deadlier for patients who catch it again, according to a report.

The whistleblowing physicians working to fight the virus in Wuhan, the epicenter of the outbreak, revealed that medically cleared patients have been getting reinfected, the Taiwan News reported.

Continue reading “Whistleblower doctors say coronavirus reinfection even deadlier” »

Apr 9, 2020

How does the coronavirus kill?

Posted by in category: biotech/medical

Doctors are reaching for drugs that dampen the immune response — but these also undermine the body’s own fight against the coronavirus. Uncertainty is hampering doctors’ ability to choose treatments.

Apr 9, 2020

SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion

Posted by in category: biotech/medical

COVID-19, the novel coronavirus disease caused by SARS-CoV-2 and outbroken at the end of 2019 in Wuhan, China, becomes a worldwide pandemic. SARS-CoV-2 belongs to the betacoronavirus genus and has 79.5% identity to SARS-CoV. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as its host entry receptor.

Apr 8, 2020

Alzheimer’s trial supports high amyloid levels as early sign of disease

Posted by in categories: biotech/medical, government, neuroscience

An ongoing long-term trial suggests high levels of amyloid proteins in the brain do serve as an early sign of Alzheimer’s disease before cognitive decline becomes apparent.


A new study presenting the first data from a long-running US government trial is suggesting high levels of amyloid proteins in the brains of cognitively normal older adults can be an effective presymptomatic sign of early stage Alzheimer’s disease.

Over the last few decades, the amyloid hypothesis has guided the majority of research into an Alzheimer’s disease treatment. The idea is that a build up of toxic amyloid proteins in the brain, called plaques, is the primary degenerative driver behind the disease.

Continue reading “Alzheimer’s trial supports high amyloid levels as early sign of disease” »

Apr 8, 2020

Blood from recovered coronavirus victims helps patient come off ventilator in just two days

Posted by in category: biotech/medical

Utilizing the antibodies from the plasma of survivors of the coronavirus to help those who are critically ill from the coronavirus has been deemed successful:


In trial, 10 severely-ill patients made recoveries after receiving antibodies from people who had successfully fought the Covid-19 virus

Premium.

Continue reading “Blood from recovered coronavirus victims helps patient come off ventilator in just two days” »

Apr 7, 2020

A single high dose of psilocybin alters brain function up to one month later

Posted by in categories: biotech/medical, neuroscience

New research provides evidence that the active ingredient in so-called magic mushrooms can affect brain processes related to emotional functioning long after the substance has left one’s body. The findings, published in Scientific Reports, shed new light on the long-term effects of psilocybin.

Rather than examining the brain while it’s under the influence of psilocybin, the researchers from Johns Hopkins University School of Medicine were interested in the enduring impact of the substance.

“Nearly all psychedelic imaging studies have been conducted during acute effects of psychedelic drugs. While acute effects of psychedelics on the brain are of course incredibly interesting, the enduring effects of psychedelic drugs on brain function have great untapped value in helping us to understand more about the brain, affect, and the treatment of psychiatric disorders,” said Frederick S. Barrett (@FredBarrettPhD), an assistant professor and the corresponding author of the study.

Apr 6, 2020

Stability of SARS-CoV-2 in different environmental conditions

Posted by in category: biotech/medical

Is you wear a facemask please keep this in mind:

1. The Coronavirus can live on the outside of your mask for up to 7 days.

https://www.thelancet.com/journals/lanmic/article/PIIS2666&#…3/fulltext

Continue reading “Stability of SARS-CoV-2 in different environmental conditions” »

Apr 6, 2020

What Could Be The Fastest Way To End The Coronavirus Crisis?

Posted by in category: biotech/medical

A COVID-19 vaccine could be produced in record time, but that still won’t be fast enough to to solve our current pandemic. What could: treatments. Developers all over the world are working on repurposing old drugs and creating new ones to treat COVID-19, and some could be ready by April this year. The reason treatments might be available so much sooner than a vaccine has to do with safety. We spoke with a couple researchers — one developing a treatment and one developing a vaccine — about their timelines.

MORE CORONAVIRUS COVERAGE:
What Coronavirus Symptoms Look Like, Day By Day.

Why A Coronavirus Vaccine Could Be Developed In Record Time.

How Coronavirus Affects People With Diabetes, Cancer, And Other Conditions.

Continue reading “What Could Be The Fastest Way To End The Coronavirus Crisis?” »

Apr 6, 2020

COVID-19 Update 8: Zinc and chloroquine for the treatment of COVID-19?

Posted by in categories: biotech/medical, education, health, media & arts

Anecdotal evidence suggests that the combination of zinc and hydroxychloroquine may be beneficial for the treatment of Covid-19:


We have been asked again and again — “What else can I do, apart from social distancing, hand hygiene, and so on, to protect myself from COVID-19?” There are additional actions that can be taken.

Continue reading “COVID-19 Update 8: Zinc and chloroquine for the treatment of COVID-19?” »

Apr 6, 2020

A new perspective

Posted by in category: biotech/medical

The rapidly spreading COVID-19 epidemic has created an unusual situation: in each population that is infected by the virus, large parts of the population will be infected within a well-defined short time period, with near certainty. A major question is thus: Can the unusual predictability of the infections’ timing be utilized to mitigate the imminent infection’s length, severity, and probability of complications?

We suggest that priming the immune system for attack shortly before it is expected to occur, e.g. via a vaccine that elicits a broad anti-viral immune response, may have this desired effect. Early activation of the immune system would allow it to clear the infection faster and with less complications than otherwise. This would alleviate adverse clinical outcomes at the individual level, and mitigate population-level risk by reducing need for hospitalizations and decreasing the infectious period of individuals, thus slowing the epidemic’s spread and reducing its impact.

Page 36 of 58First34353637383940